Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Multi-arm Optimization of Stroke Thrombolysis (MOST)

Clinical Trial Details

The objective of this trial is to determine if argatroban or eptifibatide result in improvements in health and outcomes in stroke patients compared with placebo. This will be administrated along with rt-PA.

Key Eligibility: 
  • Open to men and women 18 years or older who have been diagnosed with acute ischemic stroke.
  • Must have been treated with rt-PA within 3 hours of stroke onset
  • Must have no known allergy to argatroban or eptifibatide
  • Detailed eligibility will be reviewed when you contact the study team.

Study contact by location

Upper East Side - Manhattan

Contact(s)

Carla Sherman
(646) 962-8284
cas9149@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1909020872

ClinicalTrials.gov:

NCT03735979

Status

Open to Enrollment

Age Group

Adult

Sponsor